243 related articles for article (PubMed ID: 29339392)
1. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.
Jumani RS; Bessoff K; Love MS; Miller P; Stebbins EE; Teixeira JE; Campbell MA; Meyers MJ; Zambriski JA; Nunez V; Woods AK; McNamara CW; Huston CD
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339392
[TBL] [Abstract][Full Text] [Related]
2. Piperazine-Derivative MMV665917: An Effective Drug in the Diarrheic Piglet Model of Cryptosporidium hominis.
Lee S; Ginese M; Girouard D; Beamer G; Huston CD; Osbourn D; Griggs DW; Tzipori S
J Infect Dis; 2019 Jun; 220(2):285-293. PubMed ID: 30893435
[TBL] [Abstract][Full Text] [Related]
3. Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model.
Stebbins E; Jumani RS; Klopfer C; Barlow J; Miller P; Campbell MA; Meyers MJ; Griggs DW; Huston CD
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006183. PubMed ID: 29309415
[TBL] [Abstract][Full Text] [Related]
4. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
[TBL] [Abstract][Full Text] [Related]
5. Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box.
Bessoff K; Spangenberg T; Foderaro JE; Jumani RS; Ward GE; Huston CD
Antimicrob Agents Chemother; 2014 May; 58(5):2731-9. PubMed ID: 24566188
[TBL] [Abstract][Full Text] [Related]
6. A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection.
Ndao M; Nath-Chowdhury M; Sajid M; Marcus V; Mashiyama ST; Sakanari J; Chow E; Mackey Z; Land KM; Jacobson MP; Kalyanaraman C; McKerrow JH; Arrowood MJ; Caffrey CR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6063-73. PubMed ID: 24060869
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment strategies and drugs in development for cryptosporidiosis.
Chavez MA; White AC
Expert Rev Anti Infect Ther; 2018 Aug; 16(8):655-661. PubMed ID: 30003818
[TBL] [Abstract][Full Text] [Related]
9. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa.
Doumbo O; Rossignol JF; Pichard E; Traore HA; Dembele TM; Diakite M; Traore F; Diallo DA
Am J Trop Med Hyg; 1997 Jun; 56(6):637-9. PubMed ID: 9230795
[TBL] [Abstract][Full Text] [Related]
10. Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin.
Oboh E; Schubert TJ; Teixeira JE; Stebbins EE; Miller P; Philo E; Thakellapalli H; Campbell SD; Griggs DW; Huston CD; Meyers MJ
J Med Chem; 2021 Aug; 64(15):11729-11745. PubMed ID: 34342443
[TBL] [Abstract][Full Text] [Related]
11. Cost-effective In Vivo and In Vitro Mouse Models for Evaluating Anticryptosporidial Drug Efficacy: Assessing Vorinostat, Docetaxel, and Baicalein.
Liu M; Zhang D; Wang D; Wu X; Zhang Y; Yin J; Zhu G
J Infect Dis; 2023 Nov; 228(10):1430-1440. PubMed ID: 37418629
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models.
Theodos CM; Griffiths JK; D'Onfro J; Fairfield A; Tzipori S
Antimicrob Agents Chemother; 1998 Aug; 42(8):1959-65. PubMed ID: 9687390
[TBL] [Abstract][Full Text] [Related]
13. Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis.
Lunde CS; Stebbins EE; Jumani RS; Hasan MM; Miller P; Barlow J; Freund YR; Berry P; Stefanakis R; Gut J; Rosenthal PJ; Love MS; McNamara CW; Easom E; Plattner JJ; Jacobs RT; Huston CD
Nat Commun; 2019 Jun; 10(1):2816. PubMed ID: 31249291
[TBL] [Abstract][Full Text] [Related]
14. Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
Rueda C; Fenoy S; Simón F; Del Aguila C
Antimicrob Agents Chemother; 2008 Mar; 52(3):1150-2. PubMed ID: 18160525
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
Nachipo P; Hermann D; Quinnan G; Gordon MA; Van Voorhis WC; Iroh Tam PY
Trials; 2018 Aug; 19(1):456. PubMed ID: 30139372
[TBL] [Abstract][Full Text] [Related]
16. Emerging treatment options for cryptosporidiosis.
Love MS; Choy RKM
Curr Opin Infect Dis; 2021 Oct; 34(5):455-462. PubMed ID: 34261904
[TBL] [Abstract][Full Text] [Related]
17. The Existing Drug Vorinostat as a New Lead Against Cryptosporidiosis by Targeting the Parasite Histone Deacetylases.
Guo F; Zhang H; McNair NN; Mead JR; Zhu G
J Infect Dis; 2018 Mar; 217(7):1110-1117. PubMed ID: 29300993
[TBL] [Abstract][Full Text] [Related]
18. Amixicile Reduces Severity of Cryptosporidiosis but Does Not Have
Bartelt LA; Bolick DT; Kolling GL; Stebbins E; Huston CD; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297368
[No Abstract] [Full Text] [Related]
19. Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of
Buckner FS; Ranade RM; Gillespie JR; Shibata S; Hulverson MA; Zhang Z; Huang W; Choi R; Verlinde CLMJ; Hol WGJ; Ochida A; Akao Y; Choy RKM; Van Voorhis WC; Arnold SLM; Jumani RS; Huston CD; Fan E
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745384
[TBL] [Abstract][Full Text] [Related]
20. Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium parvum Growth
Funkhouser-Jones LJ; Ravindran S; Sibley LD
mBio; 2020 Mar; 11(2):. PubMed ID: 32127445
[No Abstract] [Full Text] [Related]
[Next] [New Search]
